Ivermectin
- First approval year
- 1996
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Unknown
- Drug name
- Ivermectin
- heartguard
- Heartguard
- ivermectin
- Ivermectin
- sklice
- Sklice
- soolantra
- Soolantra
- stromectol
- Stromectol
- 22 23 dihydro c 076b1
- 22 23 dihydroabamectin
- 22 23 dihydroavermectin b1
- 22 23 dihydroavermectin b1a
- 22,23-dihydro c-076b1
- 22,23-dihydroabamectin
- 22,23-dihydroavermectin b1
- 22,23-dihydroavermectin b1a
- a mixture of avermectin a1a 5 o demethyl 22 23 dihydro component h2b1a and avermectin a1a 5 o demethyl 25 de 1 methylpropyl 22 23 dihydro 25 1 methylethyl component h2b1b
- A MIXTURE OF AVERMECTIN A1A, 5-O-DEMETHYL-22,23-DIHYDRO-(COMPONENT H2B1A), AND AVERMECTIN A1A, 5-O-DEMETHYL-25-DE(1-METHYLPROPYL)-22,23-DIHYDRO-25-(1-METHYLETHYL)-(COMPONENT H2B1B)
- a mixture of not less than 80 ivermectin component b1a and not more than 20 ivermectin component b1b
- A MIXTURE OF NOT LESS THAN 80% IVERMECTIN COMPONENT B1A AND NOT MORE THAN 20% IVERMECTIN COMPONENT B1B
- acarexx
- Acarexx
- albendazole and ivermectin
- bimectin
- Bimectin
- bovinet
- Bovinet
- cardomec
- Cardomec
- cardotek 30
- Cardotek 30
- cd 5024
- CD-5024
And 108 more, listed on the interactive page.
- CAS registry numbers
- 70288-86-7
- ChEMBL ID
- CHEMBL6067487
- RxNorm IDs (RxCUI)
- 6069
- FDA ingredient codes (UNII)
- 8883YP2R6D
- D11AX22
- P02CF01
Sources for recorded values
- Applicant
- MERCK SHARP DOHME
- Approval date
- 22 Nov 1996
- Application number
- NDA050742
- Patents
- 5
- Designations
- 1
- Earliest recorded loss of exclusivity
- 13 Mar 2034
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Over the counter
- Pharmacology name
- ivermectin
- Type
- Synthetic organic
- Drug name stem
- -ectin
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- topical
- Action
- Irreversible agonist
- Action type
- IRREVERSIBLE_AGONIST
- Target
- Glycine Receptor (All subtypes)
- Gene symbol
- Glycine Receptor (All subtypes)
- Median affinity
- 6.4
- Affinity units
- pEC50
- Mechanism
- Glutamate-gated chloride channel modulator
- Action type
- MODULATOR
- Target
- Glutamate-gated chloride channel
- Protein identifier
- P91730
- Mechanism
- Glutamate-gated chloride channel modulator
- Action type
- MODULATOR
- Target
- Glutamate-gated chloride channel
- Protein identifier
- Q25634
- Action
- Positive
- Action type
- POSITIVE
- Target
- nicotinic acetylcholine receptor α7 subunit
- Gene symbol
- CHRNA7
- Protein identifier
- P36544
- Median affinity
- 5.1
- Affinity units
- pEC50
- Action
- Positive
- Action type
- POSITIVE
- Target
- P2X7
- Gene symbol
- P2RX7
- Protein identifier
- Q99572
Open Targets mechanisms
- Mechanism
- Glutamate-gated chloride channel modulator
- Action type
- MODULATOR
- Target
- Glutamate-gated chloride channel
- Condition
- Dermatitis, Atopic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000274
- Subject identifier
- D003876
- Condition
- Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000694
- Subject identifier
- D045169
- Condition
- Malaria
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001068
- Subject identifier
- D008288
- Condition
- Pneumonia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003106
- Subject identifier
- D011014
- Condition
- Acne Vulgaris
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003894
- Subject identifier
- D000152
- Condition
- Severe Dengue
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004227
- Subject identifier
- D019595
- Condition
- Leishmaniasis
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0005044
- Subject identifier
- D007896
- Condition
- Triple Negative Breast Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005537
- Subject identifier
- D064726
- Condition
- Dengue
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005547
- Subject identifier
- D003715
- Condition
- Elephantiasis, Filarial
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007272
- Subject identifier
- D004605
- Condition
- Influenza, Human
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007328
- Subject identifier
- D007251
- Condition
- Onchocerciasis, Ocular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007398
- Subject identifier
- D015827
- Condition
- Onchocerciasis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0007402
- Subject identifier
- D009855
- Condition
- Strongyloidiasis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0007501
- Subject identifier
- D013322
- Condition
- Trichuriasis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007524
- Subject identifier
- D014257
- Condition
- Blepharitis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0009536
- Subject identifier
- D001762
- Condition
- Rosacea
- Highest recorded phase
- 4
- Condition identifier
- EFO:1000760
- Subject identifier
- D012393
- Condition
- Helminthiasis
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001342
- Subject identifier
- D006373
- Condition
- Anosmia
- Highest recorded phase
- 2
- Condition identifier
- HP:0000458
- Subject identifier
- D000086582
- Condition
- Lice Infestations
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0003472
- Subject identifier
- D010373
- Condition
- Alcoholism
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0007079
- Subject identifier
- D000437
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000274
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000694
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001068
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003894
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004227
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005044
- Condition identifier
- EFO_0005537
- Condition identifier
- EFO_0005547
- Condition identifier
- EFO_0007272
- Condition identifier
- EFO_0007398
- Highest recorded phase
- 2
- Condition identifier
- EFO_0007402
- Condition identifier
- EFO_0007501
- Condition identifier
- EFO_0009536
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000760
- Condition identifier
- EFO_1001342
- Condition identifier
- HP_0000458
- Condition identifier
- HP_0000458
- Highest recorded phase
- 2
- Condition identifier
- HP_0001880
- Condition identifier
- MONDO_0003472
- Condition identifier
- MONDO_0003472
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004664
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004785
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004980
- Highest recorded phase
- 2
And 24 more, listed on the interactive page.
- Event
- abasia
- Reports
- 26
- Reporting signal score
- 40.0285
- Event
- abnormal behaviour
- Reports
- 65
- Reporting signal score
- 121.107
- Event
- acarodermatitis
- Reports
- 10
- Reporting signal score
- 33.7069
- Event
- agitation
- Reports
- 58
- Reporting signal score
- 64.1192
- Event
- anorexia
- Reports
- 42
- Reporting signal score
- 98.403
- Event
- aphasia
- Reports
- 30
- Reporting signal score
- 40.3825
- Event
- arthralgia
- Reports
- 135
- Reporting signal score
- 90.0026
- Event
- asthenia
- Reports
- 510
- Reporting signal score
- 1,002.61
- Event
- back pain
- Reports
- 178
- Reporting signal score
- 251.531
- Event
- blood pressure abnormal
- Reports
- 16
- Reporting signal score
- 26.0154
- Event
- chills
- Reports
- 81
- Reporting signal score
- 91.777
- Event
- coma
- Reports
- 192
- Reporting signal score
- 511.465
- Event
- conjunctival haemorrhage
- Reports
- 233
- Reporting signal score
- 1,173.17
- Event
- conjunctival hyperaemia
- Reports
- 15
- Reporting signal score
- 37.0892
- Event
- decubitus ulcer
- Reports
- 11
- Reporting signal score
- 19.2869
- Event
- depressed level of consciousness
- Reports
- 105
- Reporting signal score
- 216.899
- Event
- dermatitis contact
- Reports
- 19
- Reporting signal score
- 39.7571
- Event
- diarrhoea
- Reports
- 158
- Reporting signal score
- 60.2012
- Event
- difficulty in walking
- Reports
- 9
- Reporting signal score
- 20.0925
- Event
- disorientation
- Reports
- 33
- Reporting signal score
- 37.7732
- Event
- dysstasia
- Reports
- 33
- Reporting signal score
- 64.7852
- Event
- encephalopathy
- Reports
- 110
- Reporting signal score
- 277.327
- Event
- eosinophilia
- Reports
- 18
- Reporting signal score
- 19.0697
- Event
- erythema
- Reports
- 72
- Reporting signal score
- 54.0116
- Event
- expressive language disorder
- Reports
- 29
- Reporting signal score
- 159.364
And 37 more, listed on the interactive page.
- NCT00300768
- NCT00790998
- NCT03238131
- NCT03876262
- NCT04311671
- NCT04913610
- NCT05180461
- NCT00339417
- NCT01975441
- NCT04410406
- NCT00765024
- NCT01570504
- NCT03605758
- NCT04056325
- NCT04848688
- NCT00819520
- NCT00857948
- NCT00988533
- NCT00994422
- NCT01066585
- NCT01068158
- NCT03236168
- NCT03257943
- NCT03286101
- NCT03301649
And 90 more, listed on the interactive page.
- Dose
- 91 mcg/lb
- Route
- Oral
- How often
- As needed
Conditions of use
- Ensure each animal receives a complete dose based on a current body weight
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- 0006-0032
- 0299-3823
- 0591-4052
- 27241-293
- 42799-806
- 42806-017
- 45802-102
- 68308-701
- 72578-120
- 72578-223
- 72888-206
- 72888-207
- 75907-167
- 76420-619
- 50090-5587
- 63629-8754
- 68071-2242
- 70771-1728
- 70771-1731
- 71335-2946
- 72162-2294
These details could not be displayed.
Related records
Trials (212)
- A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%
- A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
- A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh
- A Pharmacokinetics (PK) Study in Lice Infested Children 6 Months to 3 Years of Age
- A Preventive Treatment for Migrant Workers at High-risk of COVID-19
- A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation
- A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects
- A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19
- A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention
- ACTIV-6: COVID-19 Study of Repurposed Medications
- ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)
- ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600)
- Adjunctive Ivermectin Mass Drug Administration for Malaria Control
- Adverse Effects of Ivermectin Used in Egypt During COVID-19
- Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients
- An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization
- Analysis of the Microbiome in Rosacea
- Assessing the Safety and Efficacy of a Combination Therapy for STH in PSAC in Bangladesh
- Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
- Better Disease Control by Multidrug Regimen in Scabies
Approved for (5)
- Helminthiasis
- Lice infestation
- Onchocerciasis
- Rosacea
- Strongyloidiasis
In development for (17)
- Acne Phase 2
- Alcohol dependence Phase 1
- Anosmia Phase 2
- Atopic eczema Phase 2
- Blepharitis Phase 3
- COVID-19 Phase 3
- Dengue disease Phase 2
- Dengue hemorrhagic fever Phase 2
- Filarial elephantiasis Phase 3
- Influenza Phase 3
- Leishmaniasis Early phase 1
- Malaria Phase 3
- Ocular onchocerciasis Phase 2
- Pneumonia Phase 3
- Severe acute respiratory syndrome Phase 3
- Trichuriasis Phase 2
- Triple-negative breast carcinoma Phase 1